What's the vehicle anyhow?, page-23

As much as it kills me to say it, I've reached the conculusion today that we are being treated like mushrooms. If management had been forthcoming about the issues in the P2 study at the AGM, could have been a whole different ball game - but blaming the P2 failure on undisclosed issues with the 'vehicle' just doesn't cut it for me and, frankly, doesn't fully explain the results.
I began to smell a rat when the BTX 1308 study results were presented as a 'method of action' study - we never did see how it impacted psoriasis thickness (the primary endpoint):
... or how it efficiacious it was:


Fully appreciate that BOT may eventually bounce back and find a path to market, I just don't like being treated like a fool.
Best of luck to all holders, but I'm sick of the spin and mumbo-jumbo from the US.

Disclosure update: Sell - No longer held.